Literature DB >> 7073935

Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.

R Shepherd, K R Harrap.   

Abstract

The steroids prednisolone and progesterone significantly altered the therapeutic indices of the alkylating agents, nitrogen mustard, melphalan, cyclophosphamide, phenyl acetic mustard and chlorambucil. For nitrogen mustard, chlorambucil and phenyl acetic mustard, prednisolone reduced host toxicity in the rat and enhanced the antitumour effectiveness against alkylating-agent-resistant strains of the Yoshida sarcoma and Walker carcinosarcoma. Progesterone also increased the therapeutic index of chlorambucil in the rat by decreasing its systemic toxicity. Two other alkylating agents, melphalan and cyclophosphamide, exhibited lower therapeutic indices in combination with prednisolone against alkylating-agent-sensitive tumours. This was due to the greater host toxicity of the combination than of the alkylating agent alone. In alkylating-agent-resistant tumours, however, a significant increase in growth delay was achieved if prednisolone was combined with the alkylating agent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073935      PMCID: PMC2010934          DOI: 10.1038/bjc.1982.69

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Thymus-derived lymphocytes sequestered in the bone marrow of hydrocortisone-treated mice.

Authors:  J J Cohen
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

2.  New platinum complexes with anti-tumour activity.

Authors:  T A Connors; M Jones; W C Ross; P D Braddock; A R Khokhar; M L Tobe
Journal:  Chem Biol Interact       Date:  1972-11       Impact factor: 5.192

3.  Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.

Authors:  J P Whitecar; G P Bodey; E J Freireich; K B McCredie; J S Hart
Journal:  Cancer Chemother Rep       Date:  1972-08

4.  Relapse patterns in Burkitt's lymphoma.

Authors:  J L Ziegler; A Z Bluming; L Fass; R H Morrow
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

5.  Modification of the alkylating ability of cyclophosphamide by fresh plasma.

Authors:  B T Hill; K R Harrap
Journal:  Chem Biol Interact       Date:  1972-07       Impact factor: 5.192

6.  Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).

Authors:  W G Tucker; R W Talley; R W Brownlee; J H Burrows; P B Stott; E L Moorhead; E L San Diego
Journal:  Cancer Chemother Rep       Date:  1968-09

7.  Walker carcinosarcoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity.

Authors:  V M Rosenoer; B C Mitchley; F J Roe; T A Connors
Journal:  Cancer Res       Date:  1966-08       Impact factor: 12.701

8.  Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard.

Authors:  L M van Putten; P Lelieveld
Journal:  Eur J Cancer       Date:  1971-02       Impact factor: 9.162

9.  Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia.

Authors:  T Han; E Z Ezdinli; K Shimaoka; D V Desai
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

10.  The selectivity of action of alkylating agents and drug resistance. II. A comparison of the effects of alkylating drugs on growth inhibition and cell size in sensitive and resistant strains of the Yoshida ascites sarcoma.

Authors:  K R Harrap; B T Hill
Journal:  Br J Cancer       Date:  1969-03       Impact factor: 7.640

View more
  4 in total

1.  The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat.

Authors:  J English; G W Aherne; J Arendt; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Effect of CD44 binding peptide conjugated to an engineered inert matrix on maintenance of breast cancer stem cells and tumorsphere formation.

Authors:  Xiaoming Yang; Samaneh K Sarvestani; Seyedsina Moeinzadeh; Xuezhong He; Esmaiel Jabbari
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

3.  Synergistic killing of human leukaemic lymphoblasts by glucocorticoids and cytosine arabinoside.

Authors:  R M Gledhill; A J Edwards; M R Norman
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

4.  Suppression of Hyperactive Immune Responses Protects against Nitrogen Mustard Injury.

Authors:  Liemin Au; Jeffrey P Meisch; Lopa M Das; Amy M Binko; Rebecca S Boxer; Amy M Wen; Nicole F Steinmetz; Kurt Q Lu
Journal:  J Invest Dermatol       Date:  2015-08-19       Impact factor: 8.551

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.